Crinetics Pharmaceuticals, Inc. (CRNX)
| Market Cap | 4.00B +29.0% |
| Revenue (ttm) | 18.07M +2,277.5% |
| Net Income | -496.39M |
| EPS | -5.13 |
| Shares Out | 105.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 344,400 |
| Open | 36.51 |
| Previous Close | 36.91 |
| Day's Range | 36.16 - 38.05 |
| 52-Week Range | 25.83 - 57.99 |
| Beta | 0.28 |
| Analysts | Strong Buy |
| Price Target | 76.13 (+100.71%) |
| Earnings Date | May 7, 2026 |
About CRNX
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candida... [Read more]
Financial Performance
In 2025, Crinetics Pharmaceuticals's revenue was $7.70 million, an increase of 640.71% compared to the previous year's $1.04 million. Losses were -$465.32 million, 55.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for CRNX stock is "Strong Buy." The 12-month stock price target is $76.13, which is an increase of 100.71% from the latest price.
News
Crinetics price target lowered to $84 from $87 at Oppenheimer
Oppenheimer lowered the firm’s price target on Crinetics (CRNX) to $84 from $87 and keeps an Outperform rating on the shares following quarterly results. Phase 3 trial in carcinoid syndrome…
Crinetics price target lowered to $95 from $97 at Citizens
Citizens lowered the firm’s price target on Crinetics (CRNX) to $95 from $97 and keeps an Outperform rating on the shares. Palsonify’s launch appears strong with expanding prescriber adoption and…
Crinetics Pharmaceuticals Earnings Call Transcript: Q1 2026
PALSONIFY’s Q1 2026 launch drove $10.3M in net product revenue and 232 new enrollments, with strong adoption across patient types and 70% reimbursement. The company maintains robust cash reserves, advances a deep pipeline, and expects to exceed 75% coverage by Q3.
Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
PALSONIFY™ (Paltusotine) Net Product Revenue of $10.3 Million for First-Quarter 2026, with 232 Enrollment Forms in the First Quarter Management Hosting Conference Call at 4:30 p.m. ET Today ...
Crinetics price target raised to $97 from $96 at Citizens
Citizens analyst Jonathan Wolleben raised the firm’s price target on Crinetics (CRNX) to $97 from $96 and keeps an Outperform rating on the shares. Palsonify has been approved across the…
Crinetics’ Palsonify approved by European Commission for acromegaly
Crinetics (CRNX) announced that the European Commission has approved Palsonify – paltusotine -, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for th...
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medica...
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026 after the...
Crinetics submits Palsonify marketing authorization application to ANVISA
Crinetics (CRNX) announced the submission of a marketing authorization application to Brazil’s National Health Surveillance Agency, or ANVISA, for Palsonify, the first once-daily, oral, selectively-ta...
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly
SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a Marketing Authorization Application (MAA) to Brazil's National Health S...
Crinetics Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
The conference highlighted a strong commercial launch for PALSONIFY, robust clinical pipeline progress, and positive payer dynamics. Key milestones include phase 3 trials for carcinoid syndrome and CAH, a positive EU regulatory outlook, and sustained funding into 2030.
Crinetics price target lowered to $96 from $105 at Citizens
Citizens lowered the firm’s price target on Crinetics (CRNX) to $96 from $105 and keeps an Outperform rating on the shares. Commentary on the Palsonify launch was consistent with management’s…
Crinetics price target lowered to $83 from $84 at Stifel
Stifel analyst Alex Thompson lowered the firm’s price target on Crinetics (CRNX) to $83 from $84 and keeps a Buy rating on the shares.
Crinetics reports Q4 EPS ($1.29), consensus ($1.37)
Reports Q4 revenue $6.16M, consensus $4.74M. “2025 was a breakout year for Crinetics (CRNX), as the approval and launch of Palsonify demonstrated our ability to bring an innovative therapy from…
Crinetics Pharmaceuticals Earnings Call Transcript: Q4 2025
2025 marked a pivotal year with the successful U.S. launch of PALSONIFY, strong early uptake, and expanding payer coverage. Robust financials, a $1.4B cash position, and advancing late-stage pipeline position the company for continued growth and innovation.
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the following two upcoming investor conferences...
Crinetics price target raised to $84 from $75 at Stifel
Stifel raised the firm’s price target on Crinetics (CRNX) to $84 from $75 and keeps a Buy rating on the shares. The Q4 pre-report surpassed early investor expectations for the…
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, Februar...
Crinetics doses first patient in BALANCE-CAH trial
Crinetics (CRNX) announced that the first patient has been dosed in the BALANCE-CAH Phase 2/3 trial evaluating investigational candidate atumelnant, a novel, once-daily oral adrenocorticotropic hormon...
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
SAN DIEGO, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the first patient has been dosed in the BALANCE-CAH Phase 2/3 trial evaluating investig...
Crinetics Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
Significant progress was made with the approval and launch of Palsinify, strong early revenue, and broad prescriber adoption. The pipeline advanced with positive atumelnant data and new clinical programs, supported by $1.4 billion in funding and a clear strategy for long-term growth.
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2026, the Compensation Committee of the Board of Directors granted non-q...
Crinetics upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Richard Law upgraded Crinetics (CRNX) to Buy from Neutral with a $67 price target after the company reported results for Cohort 4 from the Phase 2 TouCAHn…
Crinetics price target raised to $87 from $80 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Crinetics (CRNX) to $87 from $80 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid…